million proprietari triplerx cf data
proteostasi end cash million proteostasi conduct
placebo-control phase ii studi cftr corrector potenti /-
amplifi data top-lin result import show
contribut cftr amplifi posit data proteostasi could initi
phase trial next year vertex cftr modul revolution cf care
highli confid fda ema approv triplerx next-gen corrector
earli said cf heterogen diseas patient respond
europ access vertex drug limit due lack reimburs see
need addit cf therapi maxim patient respons increas access
reiter overweight trim target base lower
cf sale due competit
proj ev net cash
phase ii data expect initi phase ii studi
random cf patient homozyg heterogen
todoublet proprietari triplerx
pti orplacebo efficaci endpoint
includ sweat chlorid cfq-r data anticip
need addit cftr therapi recent host kol lunch
director european cf center countri kalydeco reimburs
sickest patient access orkambi symdeko avail
stress cf heterogen diseas patient experi vari
respons cftr modul typic group see differ
mechan therapeut profil even within class see need
cftr modul offer choic provid potenti efficaci incomplet
non-respond current approv therapi improv
gold standard regulatori endpoint part equat real world
consider includ reduct pulmonari exacerb impact non-pulmonari
diseas includ cvd diabet simpli patient feel
believ one size fit therapi cf see need addit
cf competit space proteostasi drug may fail clinic gain regulatori
proteostasi develop drug treat cystic fibrosi
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
remain overweight howev lower price target decreas
 cf sale forecast light overweight nda file
like triplerx approv earli also roll forward discount period
decreas price target base essenti enterpris valu million
specif valu proteostasi proprietari triplerx regimen million
appli standard multipl lower sale million discount back
prior valu triplerx sale million appli
multipl sale million discount back
decreas penetr vertex non-respond
valu triplerx cf sale europ million million appli
multipl sale million discount back
continu expect proteostasi may success europ vertex lack
reimburs result lower penetr
proteostasi end cash million add net cash million
vs prior net cash million divid decreas project market cap
million million share arriv lower price target pleas see
exhibit
page
thousand except per share
research develop
gener administr
compani report piper jaffray estim
current disclosur inform compani found
